Autonomix Appoints Jennifer Cook as Chief Business Officer
March 19, 2024 08:45 ET
|
Autonomix Medical, Inc.
Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19,...
Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
March 14, 2024 08:15 ET
|
Autonomix Medical, Inc.
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) --...
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
March 06, 2024 08:00 ET
|
Autonomix Medical, Inc.
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) --...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity
February 23, 2024 08:50 ET
|
Autonomix Medical, Inc.
Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29th at 12:00 PM ET THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:...
Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study
February 22, 2024 08:00 ET
|
Autonomix Medical, Inc.
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Company expects to commence patient enrollment imminently...
Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
February 16, 2024 08:00 ET
|
Autonomix Medical, Inc.
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, Feb. ...
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
February 14, 2024 08:05 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
February 01, 2024 08:35 ET
|
Autonomix Medical, Inc.
Live moderated webcast with members of the Autonomix management team on Wednesday, February 7th at 10:00 AM ET THE WOODLANDS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc....
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
January 31, 2024 08:45 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
January 30, 2024 09:05 ET
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...